Amneal Pharmaceuticals (AMRX) Raw Materials (2017 - 2020)

Amneal Pharmaceuticals' Raw Materials history runs 4 years deep, the most recent figure standing at $162.7 million for Q1 2020.

• On a quarterly basis, Raw Materials changed N/A year-over-year to $162.7 million in Q1 2020; TTM through Mar 2020 was $162.7 million, a N/A change from a year earlier, with the FY2019 full-year figure at $172.2 million, down 5.23% from the prior year.
• Raw Materials fell to $162.7 million in Q1 2020 per AMRX's latest filing, from $172.2 million in the prior quarter.
• Across five years, Raw Materials topped out at $205.1 million in Q3 2018 and bottomed at $140.1 million in Q4 2017.
• The 4-year median for Raw Materials is $180.9 million (2018), against an average of $178.4 million.
• Across the five-year window, Raw Materials grew 29.71% in 2018 and retreated 11.13% in 2019, its largest moves.
• Year by year, Raw Materials stood at $140.1 million in 2017, then rose by 29.71% to $181.7 million in 2018, then dropped by 5.23% to $172.2 million in 2019, then fell by 5.48% to $162.7 million in 2020.
• Per Business Quant, the three latest AMRX Raw Materials figures stand at $162.7 million (Q1 2020), $172.2 million (Q4 2019), and $182.8 million (Q3 2019).